A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 810 participants.
Also called NCT04951219
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 810 participants
- Sponsor
- Madrigal Pharmaceuticals, Inc.
- Registry
-
NCT04951219
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Puerto Rico
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04951219. Randomized; triple masking; primary purpose treatment. Start 2021-07-09 (actual); primary completion 2027-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
- Condition
- Non-Alcoholic Fatty Liver Disease
- Intervention (Drug)
- Resmetirom
- Lead sponsor
- Madrigal Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct04951219- Content hash
5d32474795859dbdea3398eab3d1801d8c69f2fc27c7f6f835b17505b58ba4c5